LIMINAL BIOSCIENCES
LIVE

Serial Number

79293279

Owner

Liminal BioSciences Inc.

Attorney

Timothy H. Hiebert

Filing Date

Apr 17, 2020

Add to watchlist:

No watchlists yet
View on USPTO

LIMINAL BIOSCIENCES Trademark

Serial Number: 79293279 • Registration: 6422386

LIMINAL BIOSCIENCES is a trademark filed by Liminal BioSciences Inc. on April 17, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 45 (Legal & Security Services). The application is currently registered and active.

Owner Contact Info

Liminal BioSciences Inc. (2 trademarks)

231 Dundas St. E

Entity Type: 98

Trademark Details

Filing Date

April 17, 2020

Registration Date

July 20, 2021

Published for Opposition

May 4, 2021

Goods & Services

Manufacture of pharmaceuticals to the order and specification of others

Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of asthma; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for the treatment of brain diseases and disorders, namely, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of dandruff; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis; anti-viral agents; antibiotics; antivirals; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely, growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of erectile dysfunction; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of gastrointestinal disorders; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hypercholesterolemia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely, diabetes, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of motion sickness; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident, stroke, Parkinson's disease, multiple sclerosis, myasthenia gravis

Providing personal support services for families of patients with life threatening disorders, namely, emotional counseling and emotional support, and coordinating the procurement and administration of medication; providing companionship services for families of patients with life threatening disorders

Pharmaceutical advice; pharmaceutical consultancy services; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; providing information to patients in the field of administering medications; medical care services relating to patient treatment, excluding services in the field of psychology and mental health

Development of pharmaceutical preparations and medicines; pharmaceutical product evaluation; pharmaceutical research and development; pharmaceutical research services; research on the subject of pharmaceuticals

Filing History

CHANGE OF NAME/ADDRESS REC'D FROM IB
Dec 27, 2024 ADCH
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 26, 2021 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 26, 2021 FICS
FINAL DISPOSITION PROCESSED
Nov 26, 2021 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 20, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Jul 20, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 4, 2021 NPUB
PUBLISHED FOR OPPOSITION
May 4, 2021 PUBO
NOTIFICATION PROCESSED BY IB
May 2, 2021 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 14, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 14, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 14, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 29, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 29, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 29, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 29, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 29, 2021 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 22, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 21, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 21, 2021 TROA
REFUSAL PROCESSED BY IB
Oct 19, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 1, 2020 RFCS
REFUSAL PROCESSED BY MPU
Sep 30, 2020 RFRR
APPLICATION FILING RECEIPT MAILED
Sep 15, 2020 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 13, 2020 RFCR
NON-FINAL ACTION WRITTEN
Sep 12, 2020 CNRT
ASSIGNED TO EXAMINER
Sep 11, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 11, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 10, 2020 REPR